Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
Neoadjuvant Therapy With Herceptin and Taxol for Stage II/III Breast Cancer
Sponsor: Beth Israel Deaconess Medical Center
This PHASE2 trial investigates Breast Cancer and is currently completed. Beth Israel Deaconess Medical Center leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Dana-Farber Cancer Institute
- Genentech, Inc.
- Harold J. Burstein, MD, PhD
- Harvard Vanguard Medical Associates
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .